These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6141202)

  • 1. Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.
    Wenzel KW; Lente JR
    J Endocrinol Invest; 1983 Oct; 6(5):389-94. PubMed ID: 6141202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?
    Kabadi UM; Premachandra BN
    Endocr Pract; 2007 Oct; 13(6):615-9. PubMed ID: 17954417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW; Lente JR
    J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment.
    Hegedüs L; Hansen JM; Bech K; Kampmann JP; Jensen K; Andersen E; Hansen P; Karstrup S; Bliddal H
    Acta Endocrinol (Copenh); 1984 Dec; 107(4):482-8. PubMed ID: 6151328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
    Gedik O; Ozdemir T; Akalin S
    Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects.
    Kasagi K; Takeuchi R; Misaki T; Kousaka T; Miyamoto S; Iida Y; Konishi J
    J Endocrinol Invest; 1997 Apr; 20(4):183-8. PubMed ID: 9211123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.